Q32 Bio Inc.(QTTB)Stock Analysis

QTTB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Q32 Bio Inc. (QTTB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores QTTB at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,623 of 2,879 stocks — the bottom half of the AI-ranked universe. QTTB scores in the top quartile across institutional flow (94.2). Areas of concern include balance sheet strength (2.5) and revenue growth (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Q32 Bio Inc. reports net income of $-7.6M, free cash flow of $-6.3M. Top institutional holders of QTTB by reported 13-F value include ORBIMED ADVISORS, Atlas Venture Life Science Advisors,, Opaleye Management, based on the most recent SEC filings. QTTB trades on the Nasdaq exchange and files with the SEC under CIK 1661998. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QTTB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Q32 Bio Inc. directly from SEC EDGAR.